BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price, Quote, News and Overview
NASDAQ:BDTX - Nasdaq - US09203E1055 - Common Stock - Currency: USD
BDTX Quote, Performance and Key Statistics
1.59
-0.02 (-1.24%)
The current stock price of BDTX is 1.59 USD. In the past month the price decreased by -4.79%. In the past year, price decreased by -73.01%.
BDTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About BDTX
Company Profile
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The firm is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The firm is also focused on a development candidate against an undisclosed, validated oncogene.
Company Info
BLACK DIAMOND THERAPEUTICS I
One Main Street, 14th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: David M. Epstein
Employees: 54
Company Website: https://www.blackdiamondtherapeutics.com/
Investor Relations: https://investors.blackdiamondtherapeutics.com/
Phone: 16174175868
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
What is the stock price of BLACK DIAMOND THERAPEUTICS I today?
The current stock price of BDTX is 1.59 USD. The price decreased by -1.24% in the last trading session.
What is the ticker symbol for BLACK DIAMOND THERAPEUTICS I stock?
The exchange symbol of BLACK DIAMOND THERAPEUTICS I is BDTX and it is listed on the Nasdaq exchange.
On which exchange is BDTX stock listed?
BDTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BLACK DIAMOND THERAPEUTICS I stock?
12 analysts have analysed BDTX and the average price target is 13.67 USD. This implies a price increase of 759.62% is expected in the next year compared to the current price of 1.59. Check the BLACK DIAMOND THERAPEUTICS I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BLACK DIAMOND THERAPEUTICS I worth?
BLACK DIAMOND THERAPEUTICS I (BDTX) has a market capitalization of 90.09M USD. This makes BDTX a Micro Cap stock.
How many employees does BLACK DIAMOND THERAPEUTICS I have?
BLACK DIAMOND THERAPEUTICS I (BDTX) currently has 54 employees.
What are the support and resistance levels for BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
BLACK DIAMOND THERAPEUTICS I (BDTX) has a support level at 1.48 and a resistance level at 1.6. Check the full technical report for a detailed analysis of BDTX support and resistance levels.
Should I buy BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BDTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BDTX, evaluating the profitability, health, valuation and growth aspects
- BLACK DIAMOND THERAPEUTICS I (BDTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BLACK DIAMOND THERAPEUTICS I (BDTX) Sales and EPS estimates to see what analysts future expectations are.
- BLACK DIAMOND THERAPEUTICS I (BDTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BLACK DIAMOND THERAPEUTICS I (BDTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Chart to make your own analysis
- BLACK DIAMOND THERAPEUTICS I (BDTX) Latest news and press-releases to stay up to date.
Does BLACK DIAMOND THERAPEUTICS I (BDTX) stock pay dividends?
BDTX does not pay a dividend.
When does BLACK DIAMOND THERAPEUTICS I (BDTX) report earnings?
BLACK DIAMOND THERAPEUTICS I (BDTX) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of BLACK DIAMOND THERAPEUTICS I (BDTX)?
BLACK DIAMOND THERAPEUTICS I (BDTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.27).
What is the Short Interest ratio of BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
The outstanding short interest for BLACK DIAMOND THERAPEUTICS I (BDTX) is 18.55% of its float. Check the ownership tab for more information on the BDTX short interest.
BDTX Technical Analysis
BDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BDTX. BDTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BDTX Financial Highlights
Over the last trailing twelve months BDTX reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS increased by 32.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.81% | ||
| ROE | -83.66% | ||
| Debt/Equity | 0 |
BDTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to BDTX. The Buy consensus is the average rating of analysts ratings from 12 analysts.